Effect of single parenteral administration of marbofloxacin on bacterial load and selection of resistant Enterobacteriaceae in the fecal microbiota of healthy pigs.
Animals
Fluoroquinolones
/ pharmacology
Feces
/ microbiology
Anti-Bacterial Agents
/ pharmacology
Enterobacteriaceae
/ drug effects
Swine
Drug Resistance, Bacterial
Microbial Sensitivity Tests
/ veterinary
Bacterial Load
/ drug effects
Escherichia coli
/ drug effects
Injections, Intramuscular
/ veterinary
Escherichia coli
Antimicrobial resistance
Marbofloxacin
Pigs
Journal
BMC veterinary research
ISSN: 1746-6148
Titre abrégé: BMC Vet Res
Pays: England
ID NLM: 101249759
Informations de publication
Date de publication:
29 Oct 2024
29 Oct 2024
Historique:
received:
22
07
2024
accepted:
11
10
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
epublish
Résumé
Antimicrobial resistance (AMR) is a global concern impacting both humans, animals and their environment. The use of oral antimicrobials in livestock, particularly in pigs, has been identified as a driver in the selection of AMR bacteria. The aim of the present study was to evaluate the effects of a single intramuscular (IM) dose of marbofloxacin (8 mg/kg) on Enterobacteriaceae and E. coli populations, as well as on fluoroquinolone resistance within the fecal microbiota of pigs. Twenty healthy pigs, 60-days old, were divided into two groups: a treated group (n = 13) and a control group (n = 7) and were monitored over a 28-day experimental period. Fecal samples were collected from all animals for the isolation of E. coli and Salmonella strains. The minimum inhibitory concentration (MIC) of marbofloxacin for the isolates recovered on MacConkey agar supplemented with 1 or 4 µg/mL of marbofloxacin and for some generic E. coli isolates (recovered from MacConkey agar not supplemented with marbofloxacin) was determined using the broth microdilution method. Genomic DNA was extracted from the confirmed bacterial strains and sequenced using the Sanger method to identify mutations in the quinolone resistance determining regions (QRDRs) of the gyrA and parC genes. The single IM administration of marbofloxacin resulted in a significant decrease in Enterobacteriaceae and E. coli fecal populations from days 1 to 3 post- treatment. No Salmonella isolates were detected in either group, and no marbofloxacin-resistant E. coli isolates were identified. The MIC of the selected generic E. coli strains (n = 100) showed an increase to up to 0.5 µg/mL between days 1 and 3 post-treatment but remained below the clinical breakpoint of marbofloxacin resistance (4 µg/mL). Sequencing of these isolates revealed no mutations in gyrA and parC genes. The present study showed that this dosing regimen of marbofloxacin significantly decreases the fecal shedding of Enterobacteriaceae and E. coli populations in pigs, while limiting the selection of marbofloxacin-resistant E. coli isolates. These findings warrant validation in sick pigs to support the selective use of this antibiotic solely in cases of clinical disease, thereby minimizing the reliance on conventional (metaphylactic) group treatments in pigs.
Sections du résumé
BACKGROUND
BACKGROUND
Antimicrobial resistance (AMR) is a global concern impacting both humans, animals and their environment. The use of oral antimicrobials in livestock, particularly in pigs, has been identified as a driver in the selection of AMR bacteria. The aim of the present study was to evaluate the effects of a single intramuscular (IM) dose of marbofloxacin (8 mg/kg) on Enterobacteriaceae and E. coli populations, as well as on fluoroquinolone resistance within the fecal microbiota of pigs. Twenty healthy pigs, 60-days old, were divided into two groups: a treated group (n = 13) and a control group (n = 7) and were monitored over a 28-day experimental period. Fecal samples were collected from all animals for the isolation of E. coli and Salmonella strains. The minimum inhibitory concentration (MIC) of marbofloxacin for the isolates recovered on MacConkey agar supplemented with 1 or 4 µg/mL of marbofloxacin and for some generic E. coli isolates (recovered from MacConkey agar not supplemented with marbofloxacin) was determined using the broth microdilution method. Genomic DNA was extracted from the confirmed bacterial strains and sequenced using the Sanger method to identify mutations in the quinolone resistance determining regions (QRDRs) of the gyrA and parC genes.
RESULTS
RESULTS
The single IM administration of marbofloxacin resulted in a significant decrease in Enterobacteriaceae and E. coli fecal populations from days 1 to 3 post- treatment. No Salmonella isolates were detected in either group, and no marbofloxacin-resistant E. coli isolates were identified. The MIC of the selected generic E. coli strains (n = 100) showed an increase to up to 0.5 µg/mL between days 1 and 3 post-treatment but remained below the clinical breakpoint of marbofloxacin resistance (4 µg/mL). Sequencing of these isolates revealed no mutations in gyrA and parC genes.
CONCLUSIONS
CONCLUSIONS
The present study showed that this dosing regimen of marbofloxacin significantly decreases the fecal shedding of Enterobacteriaceae and E. coli populations in pigs, while limiting the selection of marbofloxacin-resistant E. coli isolates. These findings warrant validation in sick pigs to support the selective use of this antibiotic solely in cases of clinical disease, thereby minimizing the reliance on conventional (metaphylactic) group treatments in pigs.
Identifiants
pubmed: 39468532
doi: 10.1186/s12917-024-04329-9
pii: 10.1186/s12917-024-04329-9
doi:
Substances chimiques
marbofloxacin
8X09WU898T
Fluoroquinolones
0
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
492Informations de copyright
© 2024. The Author(s).
Références
Rhouma M, Madec J-Y, Laxminarayan R, Colistin. From the shadows to a one health approach for addressing antimicrobial resistance. Int J Antimicrob Agents. 2023;61(2):106713.
doi: 10.1016/j.ijantimicag.2023.106713
pubmed: 36640846
World Health Organization. 10 global health issues to track in 2021. https://www.who.int/news-room/spotlight/10-global-health-issues-to-track-in-2021 (2020). Accessed June 20, 2024.
World Health Organization. Global research agenda for antimicrobial resistance in human health. https://cdn.who.int/media/docs/default-source/antimicrobial-resistance/amr-spc-npm/who-global-research-agenda-for-amr-in-human-health---policy-brief.pdf?sfvrsn=f86aa073_4&download=true (2023). Accessed June 22, 2024.
Jesudason T. A new research agenda to combat antimicrobial resistance. Lancet Infect Dis. 2023;23(8):e281.
doi: 10.1016/S1473-3099(23)00446-2
pubmed: 37516131
World Health Organization. A one health priority research agenda for antimicrobial resistance. https://www.who.int/publications/i/item/9789240075924 (2023). Accessed June 22, 2024.
Dadgostar P. Antimicrobial resistance: implications and costs. Infect Drug Resist. 2019;12:3903–10. https://doi.org/10.2147/idr.S234610 .
doi: 10.2147/idr.S234610
pubmed: 31908502
pmcid: 6929930
Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55.
doi: 10.1016/S0140-6736(21)02724-0
Jonas OB, Irwin A, Berthe FCJ, Le Gall FG, Marquez PV. Drug-resistant infections: a threat to our economic future (Vol. 2): final report. Washington, D.C.: World Bank Group; 2017. http://documents.worldbank.org/curated/en/323311493396993758/final-report . HNP/Agriculture Global Antimicrobial Resistance Initiative.
Howard A, Reza N, Aston S, Woods B, Gerada A, Buchan I, et al. Antimicrobial treatment imprecision: an outcome-based model to close the data-to-action loop. Lancet Infect Dis. 2024;24(1):e47–58.
doi: 10.1016/S1473-3099(23)00367-5
pubmed: 37660712
Rhouma M, Archambault M, Butaye P. Antimicrobial use and resistance in animals from a one health perspective. Veterinary Sci. 2023;10(5):319.
doi: 10.3390/vetsci10050319
Guardabassi L, Apley M, Olsen JE, Toutain PL, Weese S. Optimization of antimicrobial treatment to minimize resistance selection. Microbiol Spectr. 2018;6(3). https://doi.org/10.1128/microbiolspec.ARBA-0018-2017 .
Rhouma M, Soufi L, Cenatus S, Archambault M, Butaye P. Current insights regarding the role of farm animals in the spread of antimicrobial resistance from a one health perspective. Veterinary Sci. 2022;9(9):480.
doi: 10.3390/vetsci9090480
FAO. Tackling antimicrobial resistance in food and agriculture. https://www.fao.org/documents/card/en?details=cc9185en (2024). Accessed June 2, 2024.
Food and Drug Administration. Evaluating the safety of antimicrobial new animal drugs with regard to their microbiological effects on bacteria of human health concern. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-152-evaluating-safety-antimicrobial-new-animal-drugs-regard-their-microbiological-effects (2023). Accessed June 24, 2024.
Little S, Woodward A, Browning G, Billman-Jacobe H. In-water antibiotic dosing practices on pig farms. Antibiotics. 2021;10(2):169.
doi: 10.3390/antibiotics10020169
pubmed: 33567569
pmcid: 7915319
Ricker N, Trachsel J, Colgan P, Jones J, Choi J, Lee J, et al. Toward antibiotic stewardship: route of antibiotic administration impacts the microbiota and resistance gene diversity in swine feces. Front Veterinary Sci. 2020;7:255.
doi: 10.3389/fvets.2020.00255
Suárez CS-S, Sanders P, Gaugain M, Viel A, Paboeuf F, Taillandier J-F, et al. Selection of antibiotic resistance in pigs after exposure to feed cross-contaminated with oxytetracycline. Vet Microbiol. 2023;287:109924.
doi: 10.1016/j.vetmic.2023.109924
Rhouma M, Braley C, Thériault W, Thibodeau A, Quessy S, Fravalo P. Evolution of pig fecal microbiota composition and diversity in response to enterotoxigenic Escherichia coli infection and colistin treatment in weaned piglets. Microorganisms. 2021;9(7):1459.
doi: 10.3390/microorganisms9071459
pubmed: 34361896
pmcid: 8306681
Georgaki D, Vandael F, Cardoso de Carvalho Ferreira H, Filippitzi ME, De Backer P, Devreese M, et al. Qualitative risk assessment of homogeneity, stability, and residual concentrations of antimicrobials in medicated feed and drinking water in pig rearing. BMC Vet Res. 2023;19(1):1–12.
doi: 10.1186/s12917-022-03555-3
Hoeltig D, Rohde J, Brunner B, Hellmann K, Grandemange E, Waldmann K-H. Efficacy of a one-shot marbofloxacin treatment on acute pleuropneumonia after experimental aerosol inoculation of nursery pigs. Porcine Health Manage. 2018;4(1):1–10.
doi: 10.1186/s40813-018-0089-2
Yang F, Liu Y, Li Z, Wang Y, Liu B, Zhao Z, et al. Tissue distribution of marbofloxacin in pigs after a single intramuscular injection. J Vet Sci. 2017;18(2):169–73. https://doi.org/10.4142/jvs.2017.18.2.169 .
doi: 10.4142/jvs.2017.18.2.169
pubmed: 27515270
pmcid: 5489463
EMEA. Committee for Veterinary Medicinal Products. Marbofloxacin Summary Report (2). https://www.ema.europa.eu/en/documents/mrl-report/marbofloxacin-summary-report-2-committee-veterinary-medicinal-products_en.pdf (1999). Accessed May 12, 2024.
Vétoquinol. Résumé des caractéristiques du produit. Forcyl Swine. https://www.ircp.anmv.anses.fr/rcp.aspx?NomMedicament=FORCYL%20SWINE%20160%20MG/ML%20SOLUTION%20INJECTABLE%20POUR%20PORCINS (2017). Accessed June 02, 2024.
Papich MG. Antimicrobial agent use in small animals what are the prescribing practices, use of PK-PD principles, and extralabel use in the United States? J Vet Pharmacol Ther. 2021;44(2):238–49.
doi: 10.1111/jvp.12921
pubmed: 33098148
Lardé H, Dufour S, Archambault M, Massé J, Roy J-P, Francoz D. An observational cohort study on antimicrobial usage on dairy farms in Quebec, Canada. J Dairy Sci. 2021;104(2):1864–80.
doi: 10.3168/jds.2020-18848
pubmed: 33272584
Serrano-Rodríguez JM, Fernández-Varón E, Rodríguez CMC, San Andrés-Larrea MI, Rubio-Langre S, de la Fe C, et al. Population pharmacokinetics and pharmacokinetic/pharmacodynamic evaluation of marbofloxacin against coagulase-negative staphylococci, Staphylococcus aureus and Mycoplasma agalactiae pathogens in goats. Res Vet Sci. 2023;159:1–10.
doi: 10.1016/j.rvsc.2023.03.026
pubmed: 37060837
El Garch F, Kroemer S, Galland D, Morrissey I, Woehrle F. Survey of susceptibility to marbofloxacin in bacteria isolated from diseased pigs in Europe. Vet Rec. 2017;180(24):591.
doi: 10.1136/vr.103954
pubmed: 28348142
Correia S, Poeta P, Hébraud M, Capelo JL, Igrejas G. Mechanisms of quinolone action and resistance: where do we stand? J Med Microbiol. 2017;66(5):551–9.
doi: 10.1099/jmm.0.000475
pubmed: 28504927
Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis. 2005;41(Supplement2):S120–6.
doi: 10.1086/428052
pubmed: 15942878
da Silva CA, Buzato AM, Romano GS, Dias CP, Souza KL, Callegari MA, et al. Comparative evaluation of the efficacy of different marbofloxacin-based products in pigs at the nursery, growth and finish phases with clinical signs of respiratory disease: Zootecnia. Semina: Ciências Agrárias. 2023;44(1):343–58.
Boubendir S, Arsenault J, Quessy S, Thibodeau A, Fravalo P, Thériault W, et al. Salmonella contamination of broiler chicken carcasses at critical steps of the slaughter process and in the environment of two slaughter plprevalencealence, genetic profiles and association with the final carcass status. J Food Prot. 2020;84(2):321–32. https://doi.org/10.4315/jfp-20-250 .
doi: 10.4315/jfp-20-250
Massé J, Dufour S, Archambault M. Characterization of Klebsiella isolates obtained from clinical mastitis cases in dairy cattle. J Dairy Sci. 2020;103(4):3392–400.
doi: 10.3168/jds.2019-17324
pubmed: 32089315
Vounba P, Rhouma M, Arsenault J, Alambédji RB, Fravalo P, Fairbrother JM. Prevalence of colistin resistance and mcr-1/mcr-2 genes in extended-spectrum β-lactamase/AmpC-producing Escherichia coli isolated from chickens in Canada, Senegal and Vietnam. J Glob Antimicrob Resist. 2019;19:222–7.
doi: 10.1016/j.jgar.2019.05.002
pubmed: 31100501
Bai H, Du J-f, Hu M, Qi J, Cai Y-n, Niu W-w, et al. Analysis of mechanisms of resistance and tolerance of Escherichia coli to enrofloxacin. Ann Microbiol. 2012;62(1):293–8.
doi: 10.1007/s13213-011-0260-3
Seo KW, Lee YJ. Molecular characterization of fluoroquinolone-resistant Escherichia coli from broiler breeder farms. Poult Sci. 2021:101250.
Schneider M, Paulin A, Dron F, Woehrlé F. Pharmacokinetics of marbofloxacin in pigs after intravenous and intramuscular administration of a single dose of 8 mg/kg: dose proportionality, influence of the age of the animals and urinary elimination. J Vet Pharmacol Ther. 2014;37(6):523–30. https://doi.org/10.1111/jvp.12125 .
doi: 10.1111/jvp.12125
pubmed: 24666477
pmcid: 4265270
Ferran AA, Bibbal D, Pellet T, Laurentie M, Gicquel-Bruneau M, Sanders P, et al. Pharmacokinetic/pharmacodynamic assessment of the effects of parenteral administration of a fluoroquinolone on the intestinal microbiota: comparison of bactericidal activity at the gut versus the systemic level in a pig model. Int J Antimicrob Agents. 2013;42(5):429–35.
doi: 10.1016/j.ijantimicag.2013.07.008
pubmed: 24021905
Lei Z, Liu Q, Xiong J, Yang B, Yang S, Zhu Q, et al. Pharmacokinetic and pharmacodynamic evaluation of marbofloxacin and PK/PD modeling against Escherichia coli in pigs. Front Pharmacol. 2017;8:542.
doi: 10.3389/fphar.2017.00542
pubmed: 28871226
pmcid: 5566571
Lhermie G, Dupouy V, El Garch F, Ravinet N, Toutain P-L, Bousquet-Mélou A, et al. Impact of low and high doses of marbofloxacin on the selection of resistant Enterobacteriaceae in the commensal gut flora of young cattle: discussion of data from 2 study populations. Foodborne Pathog Dis. 2017;14(3):152–9.
doi: 10.1089/fpd.2016.2176
pubmed: 28072925
Rhouma M, Beaudry F, Theriault W, Bergeron N, Beauchamp G, Laurent-Lewandowski S, et al. In vivo therapeutic efficacy and pharmacokinetics of colistin sulfate in an experimental model of enterotoxigenic Escherichia coli infection in weaned pigs. Vet Res. 2016;47(1):58. https://doi.org/10.1186/s13567-016-0344-y .
doi: 10.1186/s13567-016-0344-y
pubmed: 27234971
pmcid: 4884413
Marchetti R, Faeti V, Gallo M, Pindo M, Bochicchio D, Buttazzoni L, et al. Protein content in the diet influences growth and diarrhea in weaning piglets. Animals. 2023;13(5):795.
doi: 10.3390/ani13050795
pubmed: 36899653
pmcid: 10000050
René R, Sebastian V, Marlies D, Lukas S, Annemarie K, Andrea L. Risk factors associated with post-weaning diarrhoea in Austrian piglet-producing farms. Porcine Health Manage. 2023;9(1):1–12.
doi: 10.1186/s40813-023-00315-z
Luppi A. Swine enteric colibacillosis: diagnosis, therapy and antimicrobial resistance. Porcine Health Manage. 2017;3(1):1–18.
doi: 10.1186/s40813-017-0063-4
García V, García-Meniño I, Gómez V, Jiménez-Orellana M, Méndez A, Aguarón A, et al. Mobile colistin resistance (MCR), extended-spectrum beta-lactamase (ESBL) and multidrug resistance monitoring in Escherichia coli (commensal and pathogenic) in pig farming: need of harmonized guidelines and clinical breakpoints. Front Microbiol. 2022;13:1042612.
doi: 10.3389/fmicb.2022.1042612
pubmed: 36532469
pmcid: 9756432
Viel A, Nouichi A, Le Van Suu M, Rolland J-G, Sanders P, Laurentie M, et al. PBPK model to predict marbofloxacin distribution in edible tissues and intestinal exposure in pigs. J Agric Food Chem. 2023;71(10):4358–70.
doi: 10.1021/acs.jafc.2c06561
pubmed: 36877630
Public Health Agency of Canada. FoodNet Canada Annual Report 2018. https://www.canada.ca/en/public-health/services/surveillance/foodnet-canada/publications/foodnet-canada-annual-report-2018.html (2019). Accessed June 19, 2024.
Farzan A, Friendship RM, Dewey CE, Poppe C, Funk J, Muckle CA. A longitudinal study of the Salmonella status on Ontario swine farms within the time period 2001–2006. Foodborne Pathog Dis. 2008;5(5):579–88.
doi: 10.1089/fpd.2007.0074
pubmed: 18681793
Rajiċ A, Keenliside J, McFall ME, Deckert AE, Muckle AC, O’Connor BP, et al. Longitudinal study of Salmonella species in 90 Alberta swine finishing farms. Vet Microbiol. 2005;105(1):47–56.
doi: 10.1016/j.vetmic.2004.10.005
pubmed: 15607083
Letellier A, Messier S, Quessy S. Prevalence of Salmonella spp. and Yersinia enterocolitica in finishing swine at Canadian abattoirs. J Food Prot. 1999;62(1):22–5.
doi: 10.4315/0362-028X-62.1.22
pubmed: 9921823
Soliani L, Rugna G, Prosperi A, Chiapponi C, Luppi A. Salmonella infection in pigs: Disease, prevalence, and a link between swine and human health. Pathogens. 2023;12(10):1267.
doi: 10.3390/pathogens12101267
pubmed: 37887782
pmcid: 10610219
Pires A, Funk J, Bolin C. Longitudinal study of Salmonella shedding in naturally infected finishing pigs. Epidemiol Infect. 2013;141(9):1928–36.
doi: 10.1017/S0950268812002464
pubmed: 23148875
Arnold M, Cook A. Estimation of sample sizes for pooled faecal sampling for detection of Salmonella in pigs. Epidemiol Infect. 2009;137(12):1734–41.
doi: 10.1017/S0950268809002702
pubmed: 19416556
Bonardi S. Salmonella in the pork production chain and its impact on human health in the European Union. Epidemiol Infect. 2017;145(8):1513–26.
doi: 10.1017/S095026881700036X
pubmed: 28241896
pmcid: 9203350
Canadian Pork Council. PigSAFE Producer Manual http://www.cpc-ccp.com/file.aspx?id=101ace14-20d3-49d2-a629-956b43b2037c (2023). Accessed June 17, 2024.
Government of Canada. Categorization of Antimicrobial Drugs Based on Importance in Human Medicine. https://www.canada.ca/en/health-canada/services/drugs-health-products/veterinary-drugs/antimicrobial-resistance/categorization-antimicrobial-drugs-based-importance-human-medicine.html (2009). Accessed June 24, 2024.
Bhardwaj P, Kaur G, Rampal S. Impact of marbofloxacin administration on the emergence of marbofloxacin-resistant E. Coli in faecal flora of goats and elucidation of molecular basis of resistance. J Global Antimicrob Resist. 2020;21:116–23.
doi: 10.1016/j.jgar.2020.03.019
Huang K, Xu C-W, Zeng B, Xia Q-Q, Zhang A-Y, Lei C-W, et al. Dynamics of quinolone resistance in fecal Escherichia coli of finishing pigs after ciprofloxacin administration. J Vet Med Sci. 2014;76(9):1213–8.
doi: 10.1292/jvms.14-0025
pubmed: 24919413
pmcid: 4197147